The Latest Breaking News from Amgen Inc

The biotech industry is well-positioned to witness significant growth on the backs of soaring demands and government spending. Moreover, given the sector’s defensive nature, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and United Therapeutics Corp. (UTHR) might be solid buys in 2023 that could help you set for life.…

The biotech industry is rapidly growing amid rising private and government investments and technological advancements. Given the solid prospects of the industry, fundamentally strong biotech stocks Amgen (AMGN), Vertex (VRTX), United Therapeutics (UTHR), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) might be ideal long-term investments for steady returns. Keep reading.

The U.S. 2022 fourth-quarter GDP growth surpassed estimates and induced fresh optimism. On the other hand, the biotech industry is expected to witness robust demand despite macro uncertainties. So, given the stable prospects of the biotech sector, quality stocks Amgen (AMGN), BioNTech (BNTX), Exelixis (EXEL), and Taisho Pharmaceutical (TAIPY) could…

With economic growth moderating just enough to keep hopes of a Fed-engineered ‘soft landing’ alive, shares of fundamentally strong, resilient, and growing businesses AT&T (T), Amgen (AMGN), Humana (HUM) could be worth investing in for sustained risk-adjusted returns. Continue reading….

A rapidly aging population and the rise in lifestyle diseases drive the biotech industry’s growth. Through their cutting-edge research, biotech companies are coming up with new solutions to develop treatments. Given the solid long-term prospects of the industry, it could be wise to buy fundamentally strong biotech stocks Amgen Inc.…

The biotech industry is expected to thrive amid the increasing medical requirements and greater investments in research and development. Moreover, investor sentiment toward biotech stocks has dramatically improved in recent months as the recession possibilities are rising. As this sector is known to provide a hedge against market downturns, investors…

The biotech industry strengthened over the pandemic by drug and vaccine development initiatives to combat COVID-19. Moreover, significant government investments should bode well for this industry. Therefore, quality biotech stocks Amgen (AMGN) and Gilead Sciences (GILD) could be ideal buys in November. However, fundamentally weak stock Ginkgo Bioworks (DNA) might…

Stocks registered their biggest rally since 2020 yesterday, driven by the October inflation report that showed cooling price pressures. Moreover, the latest job report is raising hopes of a slower pace of rate hikes by the Fed. Therefore, we think it could be the right time for investors to buy…

After a series of consecutive aggressive rate hikes, the labor market shows some signs of cooling. Consequently, the Fed is expected to lower its hike pace. Moreover, as investors look forward to the midterm elections, fundamentally sound stocks Amgen (AMGN), Fortinet (FTNT), and BJ's Wholesale Club (BJ) might be ideal…

Leading drug maker Amgen (AMGN) delivered impressive second-quarter results. The company is well-positioned for solid long-term growth, driven by its diversified and growing product portfolio, rising demand from a rapidly aging population, and continued advancements in science and technology. Given its high profitability, attractive dividends, and bright growth prospects, we…

Favorable federal investments are anticipated to fuel further expansion in the biotech industry. Given the sector’s good prospects, quality biotech stocks Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) could be ideal buys. However, fundamentally weak stock Intra-Cellular Therapies (ITCI) might be best avoided. Read on….